Pharmsintez has completed Phase III clinical trials of Epolong preparation for the treatment of patients with chronic renal failure. The results of the Russian phase of the study, together with data collected during clinical trials of Phase I and Phase II in India, Australia and New Zealand, confirm that Epolong effectively restores hemoglobin levels while demonstrating a high safety profile. The company plans to register the drug in Russia by the end of 2021.